Geomatrix is a registered trademark of Jagotec AG. Shionogi Pharma’s use of the Geomatrix technology is under license from SkyePharma.

Low Dose SULAR (nisoldipine) Strengths for Individual Patient Hypertension Needs


Dear Pharmacist,

Shionogi Pharma, Inc. is pleased to announce the availability of SULAR with Geomatrix® Delivery System in the low dose strengths of 8.5 mg, 17 mg, 25.5 mg, and 34 mg - a once-a-day tablet proven to provide 24-hour control for hypertension.1

SULAR is supported by many valuable resources, including 400 representatives covering 23,000 physicians nationwide, physician samples, patient out-of-pocket offsets, pharmacy journal information, physician CME and pharmacist CE programs, as well as educational materials. SULAR has broad managed care and prescription insurance coverage.

The four SULAR strengths are formulated in an extended-release Geomatrix Delivery System that allows for 15% less nisoldipine per dose and provides the same efficacy as the current formulation.2

SULAR with Geomatrix Delivery System — the low dose strengths to continue to meet individual patient needs in the treatment of hypertension.

Dispense SULAR with Geomatrix Delivery System to your patients with confidence:

* Clinical significance unknown

NDC Numbers Description Strength Size WAC
(as of 3-13-08)
59630-500-10 SULAR Tablets 8.5mg 100/Bottle $181.69
59630-501-10 SULAR Tablets 17mg 100/Bottle $227.72
59630-502-10 SULAR Tablets 25.5mg 100/Bottle $248.34
59630-503-10 SULAR Tablets 34mg 100/Bottle $248.34

Important Safety Information

The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of SULAR in patients with heart failure has not been established. SULAR should be administered cautiously in patients over the age of 65 and in those with severe hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR is recommended. SULAR should not be taken with grapefruit products.

Your support is greatly appreciated.

Thank you for helping to make SULAR with Geomatrix Delivery System readily available to your physicians and their patients. If you have any questions, please contact Shionogi Pharma, Inc. Customer Relations at 1-800-849-9707 or visit www.shionogipharma.com.

Sincerely,

Tamala M. Winton
SULAR Product Manager

SULAR with Geomatrix Delivery System tablets are available in 8.5 mg, 17 mg, 25.5 mg, and 34 mg strengths.

back to top

Indication:
SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

 

Important Safety Information:
The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of SULAR in patients with heart failure has not been established. SULAR should be administered cautiously in patients over the age of 65 and in those with severe hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR is recommended. SULAR should not be taken with grapefruit products.

 

Please click here for full prescribing information.


Your Healthcare Provider can give you more information about Sular or call (800) 849-9707 ext 1454. Ask your Healthcare Provider if Sular may be right for you.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Images are for illustrative purposes only.


References: 1. Punzi HA, Noveck R, Weiss RJ, et al. Are there differences in the effects of long-acting calcium antagonists on ambulatory blood pressure? Extended-release nisoldipine versus amlodipine as a model. Blood Press Monit. 1998;3:267-272. 2. Data on file. Shionogi Pharma, Inc. 3. Marazzi P. A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Therapeutica. 1996;22:23-35.

back to top